Cho S-F, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195-4207.

doi:10.1182/bloodadvances.2020003740

Cho S-F, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195-4207.

Blood Adv (2020) 4 (22): 5772.

https://doi.org/10.1182/bloodadvances.2020003740

In the color keys in Figure 3 on page 4200, AMG 701 should be red and the control (ctrl) should be blue. The corrected Figure 3 is shown below. The errors have been corrected in the published article.

Figure 3.

View large Download PPT

2020

Cho S-F, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195-4207.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Cho S-F, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195-4207.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only